Nasdaq: Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment
July 10, 2025
Andrew Brenner, MD, PhD, professor and chair of neuro-oncology research with UT Health San Antonio’s Mays Cancer Center, was quoted in this article. Read More…